Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Summary

What is Cardiomyopathy?

• Heterogenous collection of pathologies; normal heart muscle stiff, thin, or fills with substances that do not belong
• Dilated CM, Hypertrophic CM (Obstructive/Non-Obstructive), RCM, ACM
• Symptoms: Shortness of breath/trouble breathing, fatigue, swelling in the ankles, feet, legs, abdomen and veins, dizziness, light-headedness, fainting during physical activity, etc.

How is Cardiomyopathy managed?

• No treatment
• Generics: Beta blockers, ACE inhibitors, ARBs, antiarrhythmics, calcium channel blockers
• Branded: SGLT2 inhibitors
• Surgically implanted devices, alcohol ablation, etc.

Why Cardiomyopathy?

• First report covering CM
• New pipeline products that are expected to be blockbusters:
Camzyos (mavacamten) & aficamten - First drugs to be indicated for obstructive HCM - First myosin inhibitors
• More closely address underlying pathophysiology of the disease

GlobalData projects the therapeutic market for cardiomyopathies within the 7MM will grow from $1.6B in 2021 at a compound annual growth rate (CAGR) of 12.4% to $5.2B by 2031.

Main drivers of growth:

• Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) launch across the 7MM
• Entresto (sacubitril + valsartan) label expansion to include CM

KEY QUESTIONS ANSWERED

Treatment for cardiomyopathies should improve over the forecast period, but unmet needs remain.

• Which unmet needs are the most pressing in the 7MM?
• Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?

Novel drugs are being developed, with 65 pipeline candidates from pre-registration to Phase III.

• What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
• What do KOLs say about their clinical and commercial positioning?

An increasing number of companies are investing in cardiomyopathies drug development.

• Which have been historically the companies leading the way?
• What new companies are emerging in the space?

Key Highlights

• The cardiomyopathies market is currently highly genericized and contains many off-label medications, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles and that they are cardiomyopathy-specific therapeutics, rather than general cardiovascular drugs.
• There is an increased focus on genetic screening and developing genetic therapeutics because cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first marketed genetic therapy, as it targets patients with DCM due to a lamin gene mutation. However, this drug will not generate significant revenue given the small size of the target patient population.
• There is not a cure for cardiomyopathies, instead the disease symptoms are managed with generic cardiovascular drugs. This remains an area of unmet need in the cardiomyopathies space.
• Camzyos was the first novel therapy launched in the cardiomyopathies market in several decades when it was marketed in 2022. Thus, there is a need for novel therapies in this space, which should be met by the extensive pipeline.

Scope

• Overview of cardiomyopathies including epidemiology, disease etiology and management.
• Topline cardiomyopathy drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
• Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global cardiomyopathy therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy

The report will enable you to -

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global cardiomyopathy therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cardiomyopathies market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global cardiomyopathy therapeutics market from 2021-2031.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.